Health
Immunotherapy extends survival in patients with advanced bladder cancer – News-Medical.Net
An immunotherapy drug called ‘avelumab’ has been shown to significantly improve survival in patients with the most common type of bladder cancer, according to results from a phase III clinical trial led by Queen Mary University of London and Barts Cancer Cent…
Reviewed by Emily Henderson, B.Sc.Sep 18 2020
An immunotherapy drug called ‘avelumab’ has been shown to significantly improve survival in patients with the most common type of bladder cancer, according to results from a phase III clinical trial led by Queen Mary University of London and Barts Cancer Centre, UK.
This is the first time an immune therapy has resulted in a survival advantage in this setting in bladder cancer, and will potentially benefit thousands of patients each year.
The resul…
-
Business23 hours agoWhat I’d buy if I had to invest $20,000 in ASX 200 shares before the weekend
-
General21 hours agoFederal government funding extends cohealth GP services until July 2026
-
General6 hours agoMildura man given 28 years to pay $73,000 in unpaid fines and tolls
-
General9 hours agoAustralia’s race to rewire the country amid a global transmission boom is not unique